Research Progress and Suggestions on China’s Drug Registration Management Based on CiteSpace Knowledge Maps

Abstract

Objective To analyze the research status and hot spots in the field of drug registration in China, and to provide some suggestions for the follow-up research. Methods CiteSpace was used to conduct literature quantitative analysis on 684 related articles from 2012 to 2022, and the knowledge map was drawn. Based on this, the main characteristics and development trends of the related studies were summarized. Results and Conclusion The number of articles published was closely related to the regulatory policy of drug registration reform. The authors of these articles did not have good continuity. Besides, research hot spots were closely related to the actual work, which was mainly around the improvement of the review and approval policy, encouraging innovative drug research and development, improving the level of new drug development and other directions. The follow-up studies should further strengthen the continuity of research and inter-agency collaboration. In addition, biomedical registration may become a new research focus in the future.

Keywords

drug registration management / application for declaration / review and approval / knowledge map / CiteSpace

References

[1] State Administration for Market Regulation. Provisions of Drug Registration (Bureau Order No.27)[EB/OL]. (2020-03-30)[2023-01-10]. http://www.nmpa.gov.cn/ws04/cl2592/376150.html.

[2] Zhang Hai. The reform of drug registration system drives the innovation of supervision mode[N]. China Medical News, 2020-08-24 (003).

[3] Zhu Juan, Wang Xiaoxi, Zhang Jingchen. Thoughts and suggestions on drug re-registration under the new situation[J]. Shanghai Medicine, 2021, 42 (13): 3-5+29.

[4] Kong Fanpu. Continue to deepen the reform of drug review and approval system and greet the party’s 20th victory with excellent results[J]. China Journal of New Drugs, 2022, 31 (18): 1761-1766.

[5] An na, Han ling, Chen Pingyan. Reflections on the real-world research of new Chinese medicine under the evidence system of “three combinations” registration and evaluation of traditional Chinese medicine[J]. China Journal of New Drugs, 2022, 31 (14): 1359-1363.

[6] Li Jie, Chen Chaomei. CiteSpace: Scientific Text Mining and Visualization[M]. Beijing: Capital Economic and Trade Press, 2016.

[7] Qu Liping, Liang Jiyi, Chen Yang, et al. Research on the current situation of research and development subjects of new Chinese medicine from the perspective of drug registration applicants[J]. Chinese Herbal Medicine, 2021, 52 (6): 1858-1864.

[8] Han Xinyue, Nie Hongtao. The interest balance and system construction of innovation and accessibility of Chinese pharmaceutical products - taking the patent linking system as an example[J]. China Pharmacy, 2021, 32 (18): 2177-2183.

[9] Wan Jing. Legislation to encourage drug innovation and strengthen intellectual property protection[N]. Legal Daily, 2022-07-08 (006).

[10] Chen Yue, Chen Chaomei, Liu Zeyuan, et al. Methodology function of CiteSpace knowledge map[J]. Science Research, 2015, 33 (2): 242-253.

[11] Hou Jianhua, Hu Zhigang. Review and prospect of cite space software application research[J]. Modern Information, 2013, 33 (4): 99-103.

[12] Wang Zongmin, Yao Liu. Analysis of the status quo of biopharmaceuticals research and development and registration in Jiangsu Province[J]. Pharmaceutical Progress, 2018, 42 (6): 435-438.